Myriad Genetics has received a second patent from the US Patent and Trademark Office for its molecular residual disease (MRD) assay, Precise MRD, which detects circulating tumor DNA in patient fluid samples.
The assay is claimed to track thousands of tumor-specific variants identified through genome-scale sequencing, enabling it to detect tumor DNA at lower levels than currently available products.
Analyst QuickTake: Myriad collaborated with the University of Texas MD Anderson Cancer Center in June 2023 and Memorial Sloan Kettering Cancer Center (MSK) in September 2023 to test the potential of its MRD testing platform as a non-invasive tool for treatment selection, monitoring disease progression, and tracking treatment response in cancer patients. The first patent for the MRD assay was granted in March 2024 .
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.